Neuroendocrine Tumor Clinical Trials

44 clinical trials for Neuroendocrine Tumor across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer — RECRUITING · PHASE1
• Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases — RECRUITING · NA
• Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes — RECRUITING · NA
• A Study of MT-4561 in Patients With Various Advanced Solid Tumors — RECRUITING · PHASE1
• RegisterNET - A Registry for Neuroendocrine Tumors in the USA and Worldwide — RECRUITING
• Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases — RECRUITING · PHASE2
• 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor — RECRUITING · PHASE1
• Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors — ACTIVE_NOT_RECRUITING · PHASE3
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor — ACTIVE_NOT_RECRUITING · PHASE3
• A PROSPECTIVE RANDOMIZED PHASE II STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® ([177LU]LU-DOTA-TATE) IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE TUMOR — TERMINATED · PHASE2
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) — ACTIVE_NOT_RECRUITING · PHASE2
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study — COMPLETED · PHASE2
• Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET — TERMINATED · PHASE1
• Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies — NOT_YET_RECRUITING · NA
• Dosimetry based PRRT versus standard dose PRRT with Lu-177-DOTATOC in NEN patients- a randomized study; a step towards tailored PRRT. — TERMINATED · PHASE2
• Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients — COMPLETED · NA
• Optimal Feeding for NET Patients — COMPLETED · NA
• Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor — COMPLETED · NA
• Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study — COMPLETED · NA
• Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study — COMPLETED
• DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor — COMPLETED · NA
• Surgical Intervention and the NETest — OTHER · NA
• Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors — TERMINATED · PHASE2
• Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) — COMPLETED
• A Study of XmAb®18087 in Subjects With NET and GIST — COMPLETED · PHASE1
• Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT — COMPLETED · PHASE2
• Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency — TERMINATED · NA
• Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor — COMPLETED · PHASE1
• A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors — COMPLETED · NA
• GA-68 DOTA-TOC of Somatostatin Positive Malignancies — TERMINATED · PHASE1
• Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors — OTHER
• AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors — COMPLETED · PHASE2
• Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors — COMPLETED · PHASE1
• 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) — WITHDRAWN · PHASE2
• Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor — COMPLETED · PHASE2
• Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors — COMPLETED · PHASE2
• Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors — COMPLETED · PHASE1
• 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors — OTHER · PHASE1
• Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy — COMPLETED · PHASE2
• Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours — OTHER
• Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization — COMPLETED · PHASE2
• Gastrointestinal Motility in Patients With Neuroendocrine Tumors — COMPLETED
• Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors — COMPLETED · PHASE2
• Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors — OTHER

Refine this search